Outcome of breast cancer patients with stage I diesease: A retrospective analysis.

Abstract

e11026 Background: Breast cancer is being diagnosed at earlier stages with the increasing use of screening mammography and public awareness. Treatment of stage I breast cancer is not established strictly and various prognostic and predictive factors are considered in treatment decisions. In this study, we aimed to determine feasible and reliable prognostic factors for using adjuvant chemotherapy in the treatment of stage I breast cancer. Methods: Patients with stage I breast cancer diagnosed in two centers, i.e. Baskent University and Hacettepe University, were retrospectively evaluated. Patient and tumor characteristics as well as patient outcomes in terms of DFS and OS were determined. Results: A total of 614 patients were identified. Median age was 50, and 44% were premenopausal. Patient characteristics were summarized in the table. Median follow-up was 38 months (6-369 mos). 38 patients relapsed on follow-up and 5 patients died. Seven of the relapses was locoregional, 29 were distant, including 10 with bone-only metastases, 19 with visceral metastases. Median DFS was 68 mos. Median OS was not reached. Five year DFS was 92% and 10 year DFS was 83%. 5 year OS was 96.8%. In multivariate analysis including age, hormone receptor status, cerbB2, grade, LV invasion, menopausal status and histological subtype, only grade 3 disease was shown to be associated with significantly increased relapse rate (OR 10, 95% CI; 1.15-86.9) Conclusions: In accordance with the pertinent literature, our findings suggest that tumor grade is strongly associated with higher risk of relapse. Further studies with molecular markers may provide beter prognostication and tailoring treatment according to the risk. [Table: see text]